05 November 2024 : Original article
The Long-Acting Glucagon-Like Peptide-2 Analog Apraglutide Enhances Intestinal Protection and Survival After Chemotherapy and Allogeneic Transplantation in Mice
Mark D. Minden1ABCDE, Cindy Audiger23BCDE, Geneviève Chabot-Roy2BCDE, Sylvie LesageDOI: 10.12659/AOT.945249
Ann Transplant 2024; 29:e945249
Figure 2 Effect of cytarabine or melphalan±apraglutide treatment on body weight change. Effect of cytarabine with or without apraglutide on body weight change at day 7 (A); effect of cytarabine with or without apraglutide on body weight change (B); and effect of melphalan with or without apraglutide on body weight change (C). (A) Data are presented as mean±SEM values (n=12–16 per group). * Significant difference relative to cytarabine/vehicle-treated animals as determined by one-way ANOVA and Newman-Keuls multiple comparison post hoc analysis. (B) Animal body weight was monitored daily. n=6–18 at time=0 for each treatment group. Data are shown as mean±SEM values. The body weight change of animals treated with cytarabine alone or in combination with apraglutide was significantly lower as compared with control/vehicle animals (statistics not shown). (C) Animal body weight was monitored daily. n=10 at time=0 for each treatment group. Data are shown as mean±SEM values. Data were analyzed using the unpaired t-test per row (plus Holm-Sidak method for multiple comparisons correction); indicates days of treatment with apraglutide. * P≤0.001 vs control. NS – non-significant; LYMPH – lymphocytes; NEUT – neutrophils; recov – recovery; WBC – white blood cells.






